SCIENCE

Personalized Medicine

SCIENCE

Personalized
Medicine

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Mutations in genomic DNA drive normal cells to become cancerous. Since each cancer has a distinct genetic fingerprint, biomarker testing allows us to identify mutations so physicians can match targeted drugs and treatments to the mutations responsible for driving cancer. This helps you achieve the best possible clinical outcome.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Mutations in genomic DNA drive normal cells to become cancerous. Since each cancer has a distinct genetic fingerprint, biomarker testing allows us to identify mutations so physicians can match targeted drugs and treatments to the mutations responsible for driving cancer. This helps you achieve the best possible clinical outcome.

PATIENT INFORMATION

Why it Matters

Targeted drugs and combination therapies can drive cancer into remission, as they achieve optimal results in subsets of patients.

Molecular diagnostic tests identify mutations that can be targeted by drugs to optimize individual patient’s treatment. Biomarker testing is used more frequently to identify targeted therapies, monitor patients, and aid in treatment decisions. This strategy is becoming a Standard of Care in hematology/oncology more than in any other field of medicine.

TECHNICAL INFORMATION

How it Works

Targeted drugs bind and shut down the activity of key aberrant proteins that drive proliferation of cancer cells.

Targeted drugs bind and shut down the activity of aberrant proteins – products of specific mutations. Patients who lack these mutations are less likely to benefit from these drugs. Fast, relatively inexpensive genetic tests can quickly inform the patient and their physician which treatments have the best chance for success.

PATIENT INFORMATION

Why it Matters

Targeted drugs and combination therapies can drive cancer into remission, as they achieve optimal results in subsets of patients.

Molecular diagnostic tests identify mutations that can be targeted by drugs to optimize individual patient’s treatment. Biomarker testing is used more frequently to identify targeted therapies, monitor patients, and aid in treatment decisions. This strategy is becoming a Standard of Care in hematology/oncology more than in any other field of medicine.

TECHNICAL INFORMATION

How it Works

Targeted drugs bind and shut down the activity of key aberrant proteins that drive proliferation of cancer cells.

Targeted drugs bind and shut down the activity of aberrant proteins – products of specific mutations. Patients who lack these mutations are less likely to benefit from these drugs. Fast, relatively inexpensive genetic tests can quickly inform the patient and their physician which treatments have the best chance for success.

PERSONALIZED MEDICINE

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

wmm2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

ALL RELATED ARTICLES ⟶

PERSONALIZED MEDICINE

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

wmm2024-10-08T03:14:44-07:00October 8th, 2024|2024 Press Releases, Press Releases|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

ALL RELATED ARTICLES ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

SCIENCE

Personalized Medicine

SCIENCE